U.S. Markets close in 4 hrs 56 mins

Med BioGene Inc. (MBI.V)


TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.0250.00 (0.00%)
As of 3:46PM EDT. Market open.
People also watch
KNE.VSVA.VMIR.VQPT.VSBM.V

Med BioGene Inc.

598 East Kent Avenue South
Vancouver, BC V5X 4V6
Canada
604-732-8821
http://www.medbiogene.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Dr. Iain Weir-Jones Ph.D., P.Eng., FGSChairman and Chief Exec. OfficerN/AN/AN/A
Mr. Ibrahim GhobrialChief Financial Officer9.4kN/AN/A
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Med BioGene Inc., a life science company, focuses on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that assists in selecting patients for adjuvant chemotherapy. The company has a collaboration agreement with the University Health Network in Toronto. Med BioGene Inc. was founded in 2002 and is headquartered in Vancouver, Canada.

Corporate Governance

Med BioGene Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.